Stem Cell Therapy Market by Type (Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy), Cell Source (Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs), Therapeutic Application, End-User - Global Forecas
Description
Stem Cell Therapy Market by Type (Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy), Cell Source (Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs), Therapeutic Application, End-User - Global Forecast 2024-2030
The Stem Cell Therapy Market size was estimated at USD 439.83 million in 2023 and expected to reach USD 493.23 million in 2024, at a CAGR 12.88% to reach USD 1,027.44 million by 2030.
Stem cell therapy refers to the medical use of stem cells to replace and repair damaged or diseased tissue or organs. This therapy is important in treating various diseases, including Parkinson's, Alzheimer's, diabetes, and heart disease, by stimulating the body's repair mechanisms. Stem cells can potentially develop many different cell types in the body during early life and growth. The prevalence of chronic diseases and favorable government initiatives for regenerative treatments worldwide boost the need for stem cell therapy. However, the concerns associated with the high cost, stringent regulations, and approval processes are a significant challenge for the key players. Companies are trying to comply with the robust standards imposed by the governments to remain agile within the spaces. Moreover, the advancements in regenerative therapy and the continuous research and development activities in stem cell therapy contribute to the future expansion of key players.
Regional Insights
In America, countries including the United States and Canada, advanced healthcare infrastructure and a high prevalence of chronic diseases have driven the need for innovative treatments such as stem cell therapy. The customer purchasing behavior reflects a greater propensity to adopt new healthcare technologies, particularly in areas such as regenerative medicine. Significant research investments and activity are evidenced by the region's major position in stem cell patents, which supports a robust and evolving therapy market. The European Union (EU) presents a diverse space for stem cell therapy, with countries including Germany, the UK, and France focusing on research and clinical applications. At the same time, the Middle East and Africa region is experiencing burgeoning interest in stem cell therapy with the huge investments in healthcare improvements and increased demand for advanced medical treatments. Initiatives such as the Dubai Cell Therapy and Regenerative Medicine Framework aim to position the region as a hub for medical tourism in stem cell therapy. Meanwhile, in Asia, countries such as China, Japan, and India reflect a rapidly expanding market for stem cell therapies, and the government's supportive policies have resulted in a flourishing environment for research and innovation. Japan's and China's progressive regulatory approach with the establishment of fast-track approval for regenerative medicine products has made these countries major spaces for stem cell therapy adoption. In India, growing healthcare infrastructure and increased public and private funding for research represent a shift towards greater usage and development of stem cell therapies.
Market Insights
- Market Dynamics
The market dynamics represent an ever-changing landscape of the Stem Cell Therapy Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.- Market Drivers
- Rising prevalence of degenerative diseases and cancer cases across the world
- Increasing government initiatives for stem cell therapy across the world
- Expansion of stem cell therapy centers and clinics
- Market Restraints
- Difficulties associated with performing stem cell therapy
- Market Opportunities
- Ongoing advancements in stem cell therapy
- Surging approvals for marketing and clinical trials for stem cell therapies and treatments
- Market Challenges
- Ethical and safety issues of stem cell-based therapy
- Market Segmentation Analysis
- Type: Increasing uses of allogeneic and autologous stem cell therapy in chronic disease treatments
- Cell Source: Rising adoption of AD-MSCs and BM-MSCs in tissue remodeling and tissue repairing
- Therapeutic Application: Growing popularity of regenerative medicine in varied therapeutics areas
- End-User: Increasing uses of stem cell therapy in academics & research centers and hospitals offering effective, safe, and standardized treatment outcomes
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Stem Cell Therapy Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Stem Cell Therapy Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments- Fujifilm to Invest USD 200 Million in Cell Therapy Production
Fujifilm Holdings Corporation is channeling a formidable USD 200 million investment into cell therapy manufacturing, anticipating substantial growth in this sector. This financial injection enhances the capabilities of two pivotal subsidiaries, Fujifilm Cellular Dynamics and Fujifilm Diosynth Biotechnologies. Fujifilm Cellular Dynamics is at the forefront of creating human-induced pluripotent stem cells and their derivatives. This investment underscores Fujifilm’s commitment to innovation and its foresight in the burgeoning field of advanced medical treatments.
Mesoblast Enters Collaboration for SR-aGVHD Trial After FDA Rejections
Mesoblast Limited, a frontrunner in regenerative medicine, announced a strategic collaboration with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to launch a pivotal clinical trial focused on Ryoncil (remestemcel-L), its innovative stem cell therapy. This trial is poised to assess the efficacy and safety of Ryoncil in treating steroid-refractory acute graft versus host disease (SR-aGvHD) in individuals aged 12 years and older.
Selecta Biosciences Announces Merger with Cartesian Therapeutics
Selecta Biosciences, Inc., a biotechnology firm, completed its merger with Cartesian Therapeutics, Inc., a significant contributor in RNA cell therapy for autoimmune diseases. This strategic merger positions the newly christened Cartesian Therapeutics, Inc. with a robust financial foundation, with a collective cash reserve of over USD 110 million. These funds are expected to accelerate Descartes-08, its RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T), through Phase 3 trials, offering a pioneering treatment for Myasthenia Gravis (MG). Moreover, the capital injection propelled the development of its expansive RNA cell therapy portfolio.
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Stem Cell Therapy Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Stem Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, Inc., Anterogen Co., Ltd., Astellas Pharma Inc., Athersys, Inc., Aurion Biotechnologies, Beike Biotechnology Co., Ltd., BrainStorm Cell Therapeutics Inc., Bristol-Myers Squibb Company, CellProthera, Fate Therapeutics, Inc., Gamida Cell Ltd., Garuda Therapeutics, Holostem Terapie Avanzate S.r.l., Jasper Therapeutics, Inc., JCR Pharmaceuticals Co., Ltd., Juvena Therapeutics Inc., Kangstem Biotech., Ltd., Kite Pharma, Inc. by Gilead Sciences, Inc., Lineage Cell Therapeutics, Inc., Lonza Group AG, Mesoblast Ltd., Novo Nordisk A/S, Plasticell, ReNeuron Group PLC, Sartorius CellGenix GmbH, SQZ Biotechnologies Company, Takara Bio Inc., U.S. Stem Cell Inc, Umoja Biopharma, and Vericel Corporation.
Market Segmentation & Coverage
This research report categorizes the Stem Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:- Type
- Allogeneic Stem Cell Therapy
- Autologous Stem Cell Therapy
- Cell Source
- Adipose Tissue-Derived MSCs
- Bone Marrow-Derived MSCs
- Placental / Umbilical Cord-Derived MSCs
- Therapeutic Application
- Cardiovascular Diseases Surgeries
- Inflammatory & Autoimmune Diseases
- Musculoskeletal Disorders
- Neurological Disorders
- Orthopedics & Rheumatoid
- Wounds & Injuries
- End-User
- Academic & Research Centers
- Ambulatory Surgical Centers
- Biotechnology & Pharmaceutical Companies
- Hospitals & Clinics
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
Please Note: PDF & Excel + Online Access - 1 Year
- Americas
- Market Drivers
Table of Contents
193 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising prevalence of degenerative diseases and cancer cases across the world
- 5.1.1.2. Increasing government initiatives for stem cell therapy across the world
- 5.1.1.3. Expansion of stem cell therapy centers and clinics
- 5.1.2. Restraints
- 5.1.2.1. Difficulties associated with performing stem cell therapy
- 5.1.3. Opportunities
- 5.1.3.1. Ongoing advancements in stem cell therapy
- 5.1.3.2. Surging approvals for marketing and clinical trials for stem cell therapies and treatments
- 5.1.4. Challenges
- 5.1.4.1. Ethical and safety issues of stem cell-based therapy
- 5.2. Market Segmentation Analysis
- 5.2.1. Type: Increasing uses of allogeneic and autologous stem cell therapy in chronic disease treatments
- 5.2.2. Cell Source: Rising adoption of AD-MSCs and BM-MSCs in tissue remodeling and tissue repairing
- 5.2.3. Therapeutic Application: Growing popularity of regenerative medicine in varied therapeutics areas
- 5.2.4. End-User: Increasing uses of stem cell therapy in academics & research centers and hospitals offering effective, safe, and standardized treatment outcomes
- 5.3. Market Trend Analysis
- 5.3.1. Rigorous stem cell therapy based research initiatives, evolving regulatory frameworks, and an increasing demand for advanced therapies is fueling market in Americas
- 5.3.2. Advancements in stem cell therapies backed by government fundings and rising adoption due to medical tourism practices in the APAC countries
- 5.3.3. Strong network of academic institutions and biotech firms backed by government funding to accelerate stem cell research and commercialization in EMEA
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework Analysis
- 6. Stem Cell Therapy Market, by Type
- 6.1. Introduction
- 6.2. Allogeneic Stem Cell Therapy
- 6.3. Autologous Stem Cell Therapy
- 7. Stem Cell Therapy Market, by Cell Source
- 7.1. Introduction
- 7.2. Adipose Tissue-Derived MSCs
- 7.3. Bone Marrow-Derived MSCs
- 7.4. Placental / Umbilical Cord-Derived MSCs
- 8. Stem Cell Therapy Market, by Therapeutic Application
- 8.1. Introduction
- 8.2. Cardiovascular Diseases Surgeries
- 8.3. Inflammatory & Autoimmune Diseases
- 8.4. Musculoskeletal Disorders
- 8.5. Neurological Disorders
- 8.6. Orthopedics & Rheumatoid
- 8.7. Wounds & Injuries
- 9. Stem Cell Therapy Market, by End-User
- 9.1. Introduction
- 9.2. Academic & Research Centers
- 9.3. Ambulatory Surgical Centers
- 9.4. Biotechnology & Pharmaceutical Companies
- 9.5. Hospitals & Clinics
- 10. Americas Stem Cell Therapy Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Stem Cell Therapy Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Stem Cell Therapy Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. Market Share Analysis, 2023
- 13.2. FPNV Positioning Matrix, 2023
- 13.3. Competitive Scenario Analysis
- 13.3.1. Fujifilm to Invest USD 200 Million in Cell Therapy Production
- 13.3.2. Mesoblast Enters Collaboration for SR-aGVHD Trial After FDA Rejections
- 13.3.3. Selecta Biosciences Announces Merger with Cartesian Therapeutics
- 13.3.4. Takara Bio Enters into a License Agreement of RetroNectin with Fondazione Telethon ETS
- 13.3.5. Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale
- 13.3.6. Novo Nordisk Foundation Invests USD 135 Million to Build Cell Therapy Plant
- 13.3.7. BioLineRx Announces FDA Approval of APHEXDA (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma
- 13.3.8. BlueRock Therapeutics and bit.bio Announce Collaboration and Option Agreement for the Discovery and Manufacture of Regulatory T Cell (Treg) based Therapies
- 13.3.9. StemCyte Signs a Cooperation Agreement with a Cutting-edge U.S. immune Cell Therapy Company to Supply Drug Preparation Raw Materials for Allogeneic Modified Cell Therapy
- 13.3.10. CIRM Invests USD 89 Million in Stem Cell and Gene Therapy Research
- 13.3.11. Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
- 13.3.12. Novo Nordisk to Expand R&D Presence in Greater Boston Area
- 13.3.13. Garuda Therapeutics Secures USD 62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
- 13.3.14. BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients
- 13.3.15. ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, Furthering its Ambition to Become the Global Player in Regenerative Therapies
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.2. Key Product Portfolio
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
